introduction
A biomarker is a biological characteristic of a patient or of a disease that is a sign of a normal or abnormal process, or of a condition or disease. Predictive biomarkers are biological characteristics that predict drug's efficacy. Pharmacodynamic (PD) biomarkers reflect the biological activity of a drug and thereby are better assessed by taking repeated samples. In oncology, PD biomarkers include changes in tumor tissue, or in surrogate tissues such as skin, hair follicles, peripheral blood mononuclear cells and circulating tumor cells. They also include changes observed on functional imaging such as in positron emission tomography (PET). Conversely, prognostic biomarkers are biological characteristics that reflect the outcome of patients independent of any intervention.
The identification of predictive biomarkers of drug efficacy is essential in order to be able to select patients who will most likely benefit from anticancer drugs, and therefore avoid treating patients with ineffective therapies. This quest has even become a priority with the emergence of molecularly targeted agents that specifically modulate signaling pathways thought to be crucial for tumor proliferation, development of metastases, angiogenesis, etc. While predictive biomarkers have been identified for some molecularly targeted agents such as the human epidermal growth factor 2 (HER-2) and the epidermal growth factor receptor targeting agents, some classes of molecularly targeted agents, such as antiangiogenic agents and mammalian target of rapamycin inhibitors, still lack validated predictive biomarkers of efficacy. Predictive biomarkers of efficacy of anticancer drugs have been identified in various settings: (i) during preclinical evaluation (e.g. HER-2 overexpression or amplification for trastuzumab efficacy in breast cancer), (ii) in phase I trials (e.g. ALK translocation for crizotinib efficacy in lung adenocarcinoma), and from retrospective subgroup analyses from randomized trials (e.g. KRAS mutations for cetuximab efficacy in colorectal cancer) [1] [2] [3] . No PD biomarkers of treatment efficacy have been validated for use in clinical practice in oncology to date.
Overall, the evaluation of potential predictive and PD biomarkers has mainly been performed in phase I trials in patients with metastatic disease that has been highly altered by previous therapies [4] . While guidelines for the development and incorporation of biomarker studies in early phase clinical trials have recently been published, no clear recommendations exist for the design of trials that specifically aim at identifying biomarkers [5] . Preoperative trials have been advocated to be one of the best settings to identify predictive and PD biomarkers for two reasons [6] . First, patients included in these studies are treatment naïve which allows evaluating treatment effects on tumor tissue that has not been modified by previous therapies. Secondly, the post-treatment tumor tissue can be easily obtained during surgery, avoiding the need for additional tumor biopsies. Multiple issues are, however, associated with these trials, including the optimal duration of treatment, potential delay of surgery, experimental design, safety of such interventions, sample size calculation, etc. As an example, the POETIC trial illustrates these issues and assessed the prognostic value of the biomarker Ki67 in patients treated with hormone therapy before surgery [7] .
The present study aimed at evaluating how preoperative biomarkers trials have been designed to date by reviewing all published trials in the literature.
materials and methods

search strategy and studies selection
Eligible trials for our study were all clinical trials of cancer patients treated with anticancer drugs in the preoperative setting published in the English language. Only trials incorporating a PD end point in their design were included. Trials with a preoperative radiotherapy component were excluded.
To retrieve these trials, a Medline search was performed using the following search terms: '(presurgical [ The term 'neoadjuvant' was not included in the search strategy, as our study initially aimed at identifying preoperative biomarkers studies. Abstracts of references that appeared potentially eligible for inclusion were examined and, if deemed relevant, full-text articles were retrieved and included if appropriate.
Following these criteria, a total of 367 trials were identified, and 56 were considered eligible. Three hundred eleven trials were excluded because no PD end point was incorporated in their designs.
data extraction
Data extraction of relevant information was undertaken and recorded in a computerized database. The following data were abstracted: tumor type and stage, recruitment period, randomization, number of patients, performance status (PS) and age allowed at study entry, therapy evaluated, duration of preoperative treatment, information regarding the need to postpone surgery, sample size calculation, end points used, safety of the medical intervention, and the ability to identify predictive or PD biomarkers.
results
studies and population characteristics
The 56 identified trials were published between January 1993 and April 2015, with only five trials (9%) published before 2004 (Table 1) . Of these, 46 were phase II trials (82%), while the remaining were phase I (9%), phase I/II (4%), and phase III trials (5%). Twenty-seven of the 56 trials (48%) were randomized. In 15 of these 27 randomized trials (56%), there was a 'no treatment' arm in six trials or a placebo arm in nine trials. The remaining 29 were single-arm trials. In 35 of the 56 trials (62%), the date of surgery was fixed before study entry, while in the remaining 21 trials (37%) the date of surgery was set after the end of the preoperative study treatment.
Tumor types evaluated included breast cancer in 33 trials (59%), followed by prostate cancer in 6 trials (11%), colorectal cancer, non small-cell lung cancer (NSCLC), gastric cancer, and head and neck squamous cell carcinoma (HNSCC) in 3 trials (5%) each, pancreatic cancer in 2 trials (4%), and ovarian cancer, endometrial cancer, and gastrointestinal stromal tumor A DACH platinum complex. b.i.d., twice a day; CEF, cisplatin + epirubicin + 5-FU; D, docetaxel; EP, epirubicin + paclitaxel; FEC, 5-FU + epirubicin + cyclophosphamide; GIST, gastrointestinal stromal tumor; HNSCC, head and neck squamous cell carcinoma; IL2, interleukin 2; NSCLC, nonsmall-cell lung cancer; ORR, overall response rate; OS, overall survival; P, paclitaxel; pCR, pathologic complete response; PD, pharmacodynamic; q3w, every three weeks; qd, daily; RFS, relapse-free survival; s.c., subcutaneous; T, trastuzumab; TAC, paclitaxel + adriamycin + cyclophosphamide. in 1 trial (2%) each. In all but two trials (96%), patients had to have a fully resectable disease at presentation.
A total of 4690 patients were included in these 56 trials, with a median of 45 patients per trial (range: 5-698). Four hundred eighty-two patients (10%) did not receive any preoperative treatment and 293 patients (6%) received a placebo due to randomization. Median duration of accrual in these trials was 28 months (range: 9-98) in the 43 trials in which it was mentioned. In these trials, mean number of two patients per month were included (range: 0-7). Mean number of patients included per month was one in trials in which the date of surgery was initially set, when compared with three per month in trials in which the date of surgery was set up after the end of the preoperative treatment.
PS allowed at study entry was mentioned in 33 trials (59%). In these trials, patients had to have a PS of 0, ≤1, ≤2 or to be fit for surgery, in 5 (15%), 20 (61%), 7 (21%) and 1 (3%) trials, respectively. Information regarding maximum age allowed at study entry was mentioned in 30 trials (54%). Within these 30 trials, there was no limit in 17 trials (57%), while an age limit of 65 and 70 years was set in 1 trial (3%), and 8 trials (27%), respectively. An age limit of 75 and 80 years was set in 2 trials (7%), respectively.
characteristics of the treatments
At least one noncytotoxic agent was administered in 49 of the 56 trials (88%), including a molecularly targeted agent (26 trials, 53%), a modulator of metabolism (15 trials, 31%), immunotherapy (4 trials, 8%), and hormone therapy (9 trials, 18%). In 37 of the 56 trials (66%), a single agent was administered. Route of administration of drugs involved was oral in 34 trials (61%), intravenous in 13 trials (23%), subcutaneous in 3 trials (5%), intratumoral in 1 trial (2%), and a combination of intravenous and oral drugs in 5 trials (9%).
Among the 35 trials in which the date of surgery was fixed before study entry, all treatments were noncytotoxic agents, whereas 13 of the 21 trials (62%) in which surgery was set up after preoperative therapy included a cytotoxic agent. Among the 35 trials in which the date of surgery was fixed, treatments were administered on a daily basis in 30 trials (86%), on a weekly basis in 3 trials (9%), and once intratumorly in 1 trial (3%). Within these 35 trials, duration of therapy was a fixed number of days in 22 trials (63%), while it was within a prespecified range of days in 12 trials (34%). Median duration of therapy was 17 days (range: 1-112) in the 22 trials in which duration of preoperative therapy was a fixed number of days. Therapy was administered up to the date of surgery in one trial. In the 21 trials in which surgery was set up at the end of the preoperative study treatment, the median duration of treatment was 12 weeks and ranged from 4 to 29 weeks.
end points and sample size calculation
The primary end point of the study was mentioned in 45 of the 56 trials (80%). Within these 45, the primary end point was a PD end point in 26 (58%), efficacy in 14 (31%), and safety in 5 trials (11%). The primary PD end point was Ki67 expression decrease in 19 of the 26 trials in which the primary end point was a PD end point (73%). Within the 27 trials in which the date of surgery was initially fixed and in which the primary end point was reported, the primary end point was a PD end point in 21 trials (78%), while efficacy and safety were the primary end points in two (7%) and four trials (15%), respectively. Within the 18 trials in which surgery was set up after the end of the preoperative treatment and in which the primary end point was reported, efficacy was the primary end point in 12 trials (67%), while a PD end point and safety were the primary end points in 5 trials (28%) and 1 trial (5%), respectively.
Secondary end points included safety (27 trials, 48%), overall response rate (15 trials, 27%), pathologic complete response ( pCR) rate (10 trials, 18%), disease-free survival (9 trials, 16%), pharmacokinetics (10 trials, 18%), overall survival (7 trials, 12%), organ-sparing surgery (9 trials, 16%), change on PET imaging (3 trials, 5%), time-to-treatment failure (3 trials, 5%), and quality of life (1 trial, 2%). Within the 14 trials in which pCR was recorded, a total of 11% of patients experienced a pCR.
Information regarding sample size calculation was present in 35 of the 56 trials (62%). The alpha level used was reported in 43 of the 56 trials (77%). The alpha level used was 5% in 38 trials (88%), 10% in 4 trials (9%), and 2.5% in 1 trial (2%). Within the 29 trials in which it was reported, the alpha level was two-sided in 25 (86%) and one-sided in 4 trials (14%). The power was reported in 32 of the 56 trials (57%). Within these 32 trials, the power was 80% in 19 trials (34%), 90% in 8 trials (14%), 85%, 92%, 95%, 99%, and not a priori determined in the remaining 5 trials.
safety of the preoperative treatment
Within the 4208 patients who received a preoperative treatment, there were two deaths (0.05%) related to the study drug. Treatment had to be interrupted because of adverse events in 180 patients (4%). Three hundred fourteen of the 4690 patients (7%) could not undergo surgery as per protocol, but this was due to an adverse event in only 41 patients (1%).
identification of biomarkers
Among the 56 trials, at least one statistically significant PD biomarker was identified in 27 trials (48%), while at least one statistically significant potential predictive biomarker was identified in 17 trials (30%) ( Table 2) . However, only 8 of these 17 latter trials (47%) that identified predictive biomarkers were randomized and allowed drawing robust conclusions.
Of the 15 randomized trials with an untreated or placebo arm, changes in potential PD biomarkers were mentioned in 4 trials (27%). Statistically significant changes in the untreated/ placebo patients were found in 1 trial (6%) for Ki67 and p-AKT.
discussion
Our study reveals that preoperative trials aiming at identifying predictive or PD biomarkers are safe and still infrequent in oncology. Predictive and PD biomarkers could be identified in 30% and 48% of trials, respectively.
We identified two types of so-called preoperative biomarkers trials. The first one consists in evaluating a new drug in combination with standard chemotherapy. In these trials, surgery is set up after the end of the preoperative treatment. These treatments should be referred as neoadjuvant treatments rather than preoperative treatments. The second one is the evaluation of a noncytotoxic agent as a single agent for a short period of time. In these trials, the preoperative therapy is proposed after the date of surgery has been fixed. Overall, our data suggest that these trials are safe and feasible, and very rarely jeopardize surgery as per protocol. Preoperative trials are characterized by a slow accrual, as opposed to neoadjuvant trials. This might well be explained by the fact that a short administration of a preoperative therapy is unlikely to translate into a clinical benefit for patients. In trials with a neoadjuvant component, accrual is faster but still slow. Patients with nonmetastatic curable disease might not be keen to receive an additional drug for which it still remains to be demonstrated that they provide any clinical benefit. Slow accrual might also account for the frequent necessity to perform a second pretreatment biopsy, the first one being carried out for diagnosis purposes. We acknowledge that our search strategy did not encompass all neoadjuvant clinical trials as our initial aim was to focus on window of opportunity preoperative trials.
The trials reviewed in our study varied in terms of designs. The vast majority of trials were phase II trials using a same dose of study drug for all patients. Duration of study treatment was variable across the trials but median was short (17 days) in preoperative trials in which the date of surgery was initially fixed and the drug given as a single agent. The challenge in this latter subgroup of trials is to have patients who will be sufficiently exposed to the study drug in order to get an efficient target inhibition, as the date of surgery is fixed before the study has been proposed to the patient.
In most of the preoperative trials reviewed, there were no clear requirement regarding PS and age allowed to participate. This is in line with the fact that all patients de facto have to be fit enough to undergo surgery, and a fortiori to receive a preoperative therapy. Exclusion criteria related to co-medications might be relevant in order to avoid exposing patients to potentially harmful pharmacokinetics interactions.
Information regarding sample size calculation was infrequently reported in the trials reviewed. This determination might be challenging because of the usually large number of potential biomarkers being investigated. In addition, data regarding these biomarkers might be limited in the literature, hampering the use of published data to draw hypotheses on the variability of the measures, and the expected modification after treatment. If the data are available, there are two theoretical ways to determine the sample size. Sample size calculation can be carried out based on the data of one specific biomarker, such as Ki67 which is often used. The power of results obtained with other potential biomarkers evaluated in the study can be calculated given the number of patients determined. The second way for sample size calculation is to choose a number of patients that will provide a prespecified power for the set of potential biomarkers that is considered the most important.
Many of the trials reviewed in our study were nonrandomized trials. While single-arm studies allow evaluating PD biomarkers, they are unable to differentiate a predictive biomarker from a prognostic biomarker [6] . Randomization should be preferred in these trials as it allows evaluating not only PD biomarkers but also to claim the predictive value of potential biomarkers. The need for a control group is supported by the observation of PD changes in untreated/placebo patients, which might be due to tumor heterogeneity or the tumor biopsy itself. Randomization of a single agent versus no treatment or a placebo is the purest design but can only be envisioned if the date of surgery is not delayed. The role of a biostatistician is crucial when designing these trials, especially for the sample size calculation, in order to set up trials that will able to answer scientific questions. Finally, the design and conduct of such trials needs a close collaboration between surgeons and medical oncologists.
In conclusion, preoperative biomarkers trials are of primary importance in oncology to help identifying predictive and PD biomarkers. Archiving tissue samples for future molecular analyses should be encouraged.
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